Use of PSMA PET has been reported in some tumors with neuroendocrine characteristics, notably neuroendocrine prostate cancer (NEPC), which is a rarer and more aggressive subtype of prostate cancer compared to prostate adenocarcinoma. This evidence concerns the gene FOLH1 and prostate adenocarcinoma.